First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors.
Shanghai JMT-Bio Inc.
436 participants
Apr 11, 2025
INTERVENTIONAL
Conditions
Summary
This study is designed as an open-label, multi-center Phase 1 clinical study in participants with advanced malignant tumors to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of JMT108 injection, and to determine the RP2D/schedule for subsequent studies.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intravenous (IV) administration every three weeks (D1) in a 3-week cycle.
Intravenous (IV) administration every three weeks (D1) in a 3-week cycle.
Intravenous (IV) administration every three weeks (D1) in a 3-week cycle.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06877650